Venetoclax Basket Trial

A Phase I Study of Venetoclax in Combination With Cytotoxic Chemotherapy, Including Calaspargase Pegol, for Children, Adolescents and Young Adults With High-Risk Hematologic Malignancies

More Information

Trial Status
Accepting patients
Trial Phase
Phase 1
Enrollment
92 patients (estimated)
Sponsors
Dana-Farber Cancer Institute
Collaborators
AbbVie, University of Colorado Cancer Center, Boston Children's Hospital, Servier Pharmaceuticals LLC, Children's Cancer Research Fund, Gateway for Cancer Research
Tags
Antimetabolites, BCL-2 Inhibitor, Chemotherapy, Hypomethylating Agents (HMA), Steroid
Trial Type
Treatment
Last Update
1 month ago
SparkCures ID
1610
NCT Identifier
NCT05292664

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print a patient-friendly report to share with your patient.

We can help answer any questions and connect you (or your patient) with the study team.

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.